1887
  1. Home
  2. Eurosurveillance
  3. Volume 30, Issue 35, 04/Sep/2025
  4. Article
Surveillance Open Access
Like 0
Download

SDG 3: Antimicrobial resistance

Abstract

BACKGROUND

The COVID-19 pandemic has challenged efforts to optimise rational antibacterial use due to uncertainties in treatment protocols.

AIM

We investigated the impact of COVID-19 on hospital antibacterial consumption in Belgium from 2017 to 2022, relative to the general and hospitalised population.

METHODS

We analysed national reimbursement data using defined daily doses (DDD) and three metrics: DDD/1,000 inhabitants/day (DID), DDD/1,000 patient days (PD) and DDD/1,000 admissions. We performed linear regressions to analyse 6-year trends (2017–2022) and estimated predicted consumption from 2020 to 2022 using the compound annual growth rate from 2017 to 2019. To assess the impact of COVID-19, we compared observed and predicted relative changes in antibacterial consumption between 2019 (pre-pandemic) and 2020 (early pandemic) and between 2019 and 2022 (late pandemic).

RESULTS

From 2019 to 2020, hospital antibacterial consumption (anatomical therapeutic chemical (ATC) J01) decreased by 12% in DID but increased by 5% and 7% in DDD/1,000 PD and DDD/1,000 admissions, respectively. From 2017 to 2022, systemic antibacterials consumption declined significantly only when expressed in DID. Although all systemic antibacterial subclasses were used less than predicted between 2020 and 2022 when expressed in DID, hospital-based metrics showed higher consumption, except for macrolides and amphenicols. Broad-spectrum antibacterial consumption decreased from 2017 to 2022 when expressed in DID but fluctuated with hospital metrics, peaking in 2020, and exceeded forecasts.

CONCLUSION

COVID-19 altered trends in hospital antibacterial consumption, with contrasting patterns depending on the metric used, underline the importance of hospital-specific surveillance to support targeted stewardship and preparedness efforts.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2025.30.35.2500088
2025-09-04
2026-04-11
/content/10.2807/1560-7917.ES.2025.30.35.2500088
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/30/35/eurosurv-30-35-2.html?itemId=/content/10.2807/1560-7917.ES.2025.30.35.2500088&mimeType=html&fmt=ahah

References

  1. Murray CJL, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G, Gray A, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629-55.  https://doi.org/10.1016/S0140-6736(21)02724-0 
  2. European Commission. HEALTH UNION: Identifying top 3 priority health threats. Brussels: European Commission; 2022. Available from: https://health.ec.europa.eu/publications/hera-factsheet-health-union-identifying-top-3-priority-health-threats_en
  3. Vandael E, Magerman K, Coenen S, Goossens H, Catry B. Antibiotic consumption in Belgian acute care hospitals: analysis of the surveillance methodology, consumption evolution 2003 to 2016 and future perspectives. Euro Surveill. 2019;24(46):1900098.  https://doi.org/10.2807/1560-7917.ES.2019.24.46.1900098 
  4. Federal Public Service (FPS) Health, Food Chain Safety and Environment. Belgian “One Health” national action plan on the fight against antimicrobial resistance (AMR) 2020-2024. Brussels: FPS Health, Food Chain Safety and Environment; 2021. Available from: https://www.health.belgium.be/en/belgian-one-health-national-action-plan-fight-against-antimicrobial-resistance-2020-2024
  5. Catteau L, Kelly M, Bonacini L, Catry B. Consommation d’antimicrobiens en Belgique : résultats des surveillances ESAC-Net et BeH-SAC. [Antimicrobial consumption in Belgium: results of ESAC-Net and BeH-SAC surveillance]. Brussels: Sciensano, 2023. French. Available from: https://www.nosoinfo.be/nosoinfos/consommation-dantimicrobiens-en-belgique-resultats-des-surveillances-esac-net-et-beh-sac
  6. Butler CC, Dorward J, Yu L-M, Gbinigie O, Hayward G, Saville BR, et al. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet. 2021;397(10279):1063-74.  https://doi.org/10.1016/S0140-6736(21)00461-X 
  7. Rawson TM, Moore LSP, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M, et al. Bacterial and fungal coinfection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis. 2020;71(9):2459-68.  https://doi.org/10.1093/cid/ciaa530 
  8. Milas S, Poncelet A, Buttafuoco F, Pardo A, Lali SE, Cherifi S. Antibiotic use in patients with Coronavirus disease 2019 (COVID-19): outcomes and associated factors. Acta Clin Belg. 2022;77(3):579-87.  https://doi.org/10.1080/17843286.2021.1916300 
  9. Vlahović-Palčevski V, Rubinić I, Payerl Pal M. Impact of the COVID-19 pandemic on hospital antimicrobial consumption in Croatia. J Antimicrob Chemother. 2022;77(10):2713-7.  https://doi.org/10.1093/jac/dkac247 
  10. Stanić Benić M, Milanič R, Monnier AA, Gyssens IC, Adriaenssens N, Versporten A, et al. Metrics for quantifying antibiotic use in the hospital setting: results from a systematic review and international multidisciplinary consensus procedure. J Antimicrob Chemother. 2018;73(suppl_6):vi50-8.  https://doi.org/10.1093/jac/dky118 
  11. Rubinić I, Leung VH, Högberg LD, Monnet DL, Vlahović-Palčevski V, ESAC-Net study group. Measuring hospital antibiotic consumption in EU/EEA countries: comparison of different metrics, 2017 to 2021. Euro Surveill. 2024;29(46):2400317.  https://doi.org/10.2807/1560-7917.ES.2024.29.46.2400317 
  12. European Centre for Disease Prevention and Control (ECDC). Antimicrobial consumption (AMC) reporting protocol 2024: European Surveillance of Antimicrobial Consumption Network (ESAC-Net) surveillance data for 2023. Stockholm: ECDC; 2024.
  13. Sciensano. Belgian hospitals – surveillance of antimicrobial consumption. Brussels: Sciensano; [Accessed: 10 Jan 2025]. Available from: https://www.sciensano.be/en/projects/belgian-hospitals-surveillance-antimicrobial-consumption
  14. Meeus P, Grypdonck L, Dalcq V, Swine B, De Falleur M, Declercq K, et al. Medication use in public pharmacies: Methodology and elements of interpretation. Brussels: The National Institute for Health and Disability Insurance; 2024.
  15. European Centre for Disease Prevention and Control (ECDC). European Surveillance of Antimicrobial Consumption Network (ESAC-Net): Data collection and analysis. Stockholm: ECDC. [Accessed: 10 Jan 2025]. Available from: https://www.ecdc.europa.eu/en/about-us/networks/disease-networks-and-laboratory-networks/esac-net-data
  16. Federal Public Service Health (FPS Halth). Key figures on healthcare – general hospitals (Edition 10). Brussels: FPS Health; [Accessed: 20 Mar 2025]. Available from: https://www.health.belgium.be/sites/default/files/uploads/fields/fpshealth_theme_file/blikvanger_gezondheidszorg_az_v10.pdf
  17. World Health Organization Collaborating Centre for Drugs Statistics Methodology. DDD and ATC-classification 2024. Oslo: Norwegian Institute of Public Health; [Accessed: 15 Feb 2024]. Available from: https://www.whocc.no/atc_ddd_index
  18. Eurostat. Dataset: Population on 1 January (TPS00001). Brussels: Eurostat; [Accessed: 7 Jan 2024]. Available from: https://ec.europa.eu/eurostat/databrowser/product/view/TPS00001
  19. Wayman R. What compound annual growth rate (CAGR) tells investors. New York: Investopedia; 2025. Available from: https://www.investopedia.com/investing/compound-annual-growth-rate-what-you-should-know
  20. European Centre for Disease Prevention and Control (ECDC). Antimicrobial consumption in the EU/EEA (ESAC-Net): Annual Epidemiological Report for 2022. Stockholm: ECDC; 2023. Available from: https://www.ecdc.europa.eu/en/publications-data/surveillance-antimicrobial-consumption-europe-2022
  21. Ruzsa R, Benkő R, Hambalek H, Papfalvi E, Csupor D, Nacsa R, et al. Hospital antibiotic consumption before and during the COVID-19 pandemic in Hungary. Antibiotics (Basel). 2024;13(1):102.  https://doi.org/10.3390/antibiotics13010102 
  22. Grau S, Hernández S, Echeverría-Esnal D, Almendral A, Ferrer R, Limón E, et al. Antimicrobial consumption among 66 acute care hospitals in Catalonia: impact of the COVID-19 pandemic. Antibiotics (Basel). 2021;10(8):943.  https://doi.org/10.3390/antibiotics10080943 
  23. Friedli O, Gasser M, Cusini A, Fulchini R, Vuichard-Gysin D, Halder Tobler R, et al. Impact of the COVID-19 pandemic on inpatient antibiotic consumption in Switzerland. Antibiotics (Basel). 2022;11(6):792.  https://doi.org/10.3390/antibiotics11060792 
  24. Padullés A, Hernàndez S, Fernández-Polo A, Grau S, Almendral A, Melendo S, et al. Trends in antimicrobial consumption at 72 adult and pediatric hospitals in Catalonia. Results of the VINCat Program 2008-2022. Enferm Infecc Microbiol Clin (Engl Ed). 2025;43(Suppl 1):S69-79.
  25. Cortoos P-J, Gilissen C, Mol PGM, Van den Bossche F, Simoens S, Willems L, et al. Empirical management of community-acquired pneumonia: impact of concurrent A/H1N1 influenza pandemic on guideline implementation. J Antimicrob Chemother. 2011;66(12):2864-71.  https://doi.org/10.1093/jac/dkr366 
  26. Statistics Austria. Inpatient health care: hospital discharges. Vienna: Statistics Austria. [Accessed: 3 Oct 2024]. Available from: https://www.statistik.at/en/statistics/population-and-society/health/health-care-and-expenditure/inpatient-health-care-hospital-discharges
  27. European Centre for Disease Prevention and Control (ECDC). Assessing the health burden of infections with antibiotic-resistant bacteria in the EU/EEA, 2016-2020. Stockholm: ECDC; 2022. Available from: https://www.ecdc.europa.eu/en/publications-data/health-burden-infections-antibiotic-resistant-bacteria-2016-2020
  28. Vermeulen H, Coenen S, Hens N, Bruyndonckx R. Impact of changing reimbursement criteria on the use of fluoroquinolones in Belgium. J Antimicrob Chemother. 2021;76(10):2725-32.  https://doi.org/10.1093/jac/dkab255  PMID: 34374778 
  29. Belgisch Centrum voor Farmacotherapeutische Informatie (BCFI). Gecommentarieerd Geneesmiddelen repertorium: Ceftazidim + avibactam. [Commented drug formulary: Ceftazidime + avibactam]. Brussels: BCFI. [Accessed: 28 Nov 2024]. Dutch. Available from: https://www.bcfi.be/nl/chapters/12?frag=28829&view=pvt&vmp_group=39743
  30. Damian E, Bonacini L, Kelly M, Allaoui EM, Maertens De Noordhout C, Coenen S, et al. Monitoring community antibiotic consumption in Belgium: reimbursement versus retail data (2013-22). J Antimicrob Chemother. 2025;80(1):138-46.  https://doi.org/10.1093/jac/dkae384  PMID: 39450851 
  31. World Health Organization (WHO). ATC/DDD toolkit. Geneva: WHO. [Accessed: 10 Jan 2025]. Available from: https://www.who.int/tools/atc-ddd-toolkit
Trends in hospital antibacterial consumption: a retrospective analysis of reimbursement data, Belgium 2017 to 2022
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Laura+Bonacini&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Bonacini Laura</a>, <a href="/search?value1=Julie+Domen&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Domen Julie</a>, <a href="/search?value1=Paul+De+Munter&option1=author&noRedirect=true" class="nonDisambigAuthorLink">De Munter Paul</a>, <a href="/search?value1=Maya+Hites&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Hites Maya</a>, <a href="/search?value1=Diana+Huis+in%E2%80%98t+Veld&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Huis in‘t Veld Diana</a>, <a href="/search?value1=Antonelle+Pardo&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Pardo Antonelle</a>, <a href="/search?value1=Johan+Van+Laethem&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Van Laethem Johan</a>, <a href="/search?value1=Dirk+Vogelaers&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Vogelaers Dirk</a>, <a href="/search?value1=Boudewijn+Catry&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Catry Boudewijn</a>, <a href="/search?value1=Lucy+Catteau&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Catteau Lucy</a></span>. Trends in hospital antibacterial consumption: a retrospective analysis of reimbursement data, Belgium 2017 to 2022. <a href="/content/ecdc">Euro Surveill.</a> 2025;30(35):pii=2500088. <a href="https://doi.org/10.2807/1560-7917.ES.2025.30.35.2500088" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2025.30.35.2500088</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 03 Feb 2025;&nbsp;&nbsp; <span class="generated">Accepted</span>: 16 Apr 2025 </span> </p>
/content/10.2807/1560-7917.ES.2025.30.35.2500088
/content/10.2807/1560-7917.ES.2025.30.35.2500088
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error